Dan

PITTSBURGH, Nov. 10, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the presentation of data supporting the potential of its first and lead product candidate, BSB-1001, at the 37th Society for

PITTSBURGH, PA, November 03, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present data in a poster at the 37th Society

Industry veteran brings nearly 20 years of broad leadership experience in biopharma PITTSBURGH, PA, October 04, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, announced the appointment of Keir Loiacono, Esq. to Chief Executive

Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the company will present a poster, at the 7th Annual CAR-TCR Summit, being held in Boston, MA from September 19 –